[Development of [18F]FRP-170 injection for imaging hypoxia by PET].
A novel [18F]FRP-170 injection for imaging hypoxia by PET was developed for clinical use. The preparation was based on the simple on-column basic-hydrolysis and the whole procedure was automated by detecting He flow change for transferring and evaporating liquids. [18F]FRP-170 was prepared in around 15-20% decay-corrected radiochemical yield within 60 min and stable in saline for more than 6 hr. Radiochemical purity was over 99% and specific activity at EOS was 40-60 GBq/micromol. The radiation-absorbed dose to the whole body was estimated to be 1.0 mSv/185 MBq. The [18F]FRP-170 injection proved to be suitable for clinical use without acute toxicity or mutagenicity.
Ishikawa
Yoichi
Y
Cyclotron and Radioisotope Center, Tohoku University.
Funaki
Yoshihito
Y
Iwata
Ren
R
Furumoto
Shozo
S
Nakata
Eiko
E
Kudo
Yukitsuka
Y
Kaneta
Tomohiro
T
Hakamatsuka
Takashi
T
Takai
Yoshihiro
Y
Yamada
Shogo
S
D000818:Animals; D004304:Dosage Forms; D015195:Drug Design; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics / Q000633:toxicity; D000860:Hypoxia / Q000000981:diagnostic imaging*; D007275:Injections, Intravenous; D051379:Mice; D008815:Mice, Inbred Strains; D009152:Mutagenicity Tests; D009593:Nitroimidazoles / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000633:toxicity; D049268:Positron-Emission Tomography; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D004304:Dosage Forms; C501635:FRP-170; D005462:Fluorine Radioisotopes; D009593:Nitroimidazoles; D019275:Radiopharmaceuticals